EMEA-001864-PIP03-19
Key facts
| Invented name |
Takhzyro
|
| Active substance |
lanadelumab
|
| Therapeutic area |
Other
|
| Decision number |
P/0476/2020
|
| PIP number |
EMEA-001864-PIP03-19
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Prevention of attacks of Idiopathic non-histaminergic angioedema (INHA)
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Shire Pharmaceuticals Ireland Limited (a Takeda company)
E-mail: medinfoEMEA@shire.com
Tel: +800 66838470 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|